122 related articles for article (PubMed ID: 37987512)
1. Tanshinone IIA ameliorates cisplatin-induced toxicology and cisplatin resistance via regulating SLC7A11 expression.
Qin H; Yuan Y; Yuan M; Yi S; Yang Y; Zhang Y
Environ Toxicol; 2024 Mar; 39(3):1429-1441. PubMed ID: 37987512
[TBL] [Abstract][Full Text] [Related]
2. Tanshinone IIA induces ferroptosis in gastric cancer cells through p53-mediated SLC7A11 down-regulation.
Guan Z; Chen J; Li X; Dong N
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32776119
[TBL] [Abstract][Full Text] [Related]
3. Tanshinone IIA inhibits gastric cancer cell stemness through inducing ferroptosis.
Ni H; Ruan G; Sun C; Yang X; Miao Z; Li J; Chen Y; Qin H; Liu Y; Zheng L; Xing Y; Xi T; Li X
Environ Toxicol; 2022 Feb; 37(2):192-200. PubMed ID: 34661962
[TBL] [Abstract][Full Text] [Related]
4. Tanshinone IIA destabilizes SLC7A11 by regulating PIAS4-mediated SUMOylation of SLC7A11 through KDM1A, and promotes ferroptosis in breast cancer.
Luo N; Zhang K; Li X; Hu Y; Guo L
J Adv Res; 2024 Apr; ():. PubMed ID: 38615741
[TBL] [Abstract][Full Text] [Related]
5. Tanshinone IIA combined with cisplatin synergistically inhibits non-small-cell lung cancer in vitro and in vivo via down-regulating the phosphatidylinositol 3-kinase/Akt signalling pathway.
Liao XZ; Gao Y; Huang S; Chen ZZ; Sun LL; Liu JH; Chen HR; Yu L; Zhang JX; Lin LZ
Phytother Res; 2019 Sep; 33(9):2298-2309. PubMed ID: 31268205
[TBL] [Abstract][Full Text] [Related]
6. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
Drayton RM; Dudziec E; Peter S; Bertz S; Hartmann A; Bryant HE; Catto JW
Clin Cancer Res; 2014 Apr; 20(7):1990-2000. PubMed ID: 24516043
[TBL] [Abstract][Full Text] [Related]
7. Functional role of the SLC7A11-AS1/xCT axis in the development of gastric cancer cisplatin-resistance by a GSH-dependent mechanism.
Luo Y; Xiang W; Liu Z; Yao L; Tang L; Tan W; Ye P; Deng J; Xiao J
Free Radic Biol Med; 2022 May; 184():53-65. PubMed ID: 35367340
[TBL] [Abstract][Full Text] [Related]
8. Potentiation of the anticancer effect of doxorubicinin drug-resistant gastric cancer cells by tanshinone IIA.
Xu Z; Chen L; Xiao Z; Zhu Y; Jiang H; Jin Y; Gu C; Wu Y; Wang L; Zhang W; Zuo J; Zhou D; Luan J; Shen J
Phytomedicine; 2018 Dec; 51():58-67. PubMed ID: 30466628
[TBL] [Abstract][Full Text] [Related]
9. Tanshinone IIA acts via p38 MAPK to induce apoptosis and the down-regulation of ERCC1 and lung-resistance protein in cisplatin-resistant ovarian cancer cells.
Jiao JW; Wen F
Oncol Rep; 2011 Mar; 25(3):781-8. PubMed ID: 21165580
[TBL] [Abstract][Full Text] [Related]
10. Tanshinone IIA attenuates high glucose induced human VSMC proliferation and migration through miR-21-5p-mediated tropomyosin 1 downregulation.
Jia S; Ma WD; Zhang CY; Zhang Y; Yao ZH; Quan XH; Guo X; Wang CX
Arch Biochem Biophys; 2019 Nov; 677():108154. PubMed ID: 31672498
[TBL] [Abstract][Full Text] [Related]
11. Tanshinone IIA regulates microRNA‑125b/foxp3/caspase‑1 signaling and inhibits cell viability of nasopharyngeal carcinoma.
Wang Y; Jin W; Wang J
Mol Med Rep; 2021 May; 23(5):. PubMed ID: 33760137
[TBL] [Abstract][Full Text] [Related]
12. Potential therapeutic roles of tanshinone IIA in human bladder cancer cells.
Chiu SC; Huang SY; Chang SF; Chen SP; Chen CC; Lin TH; Liu HH; Tsai TH; Lee SS; Pang CY; Hsieh TF
Int J Mol Sci; 2014 Sep; 15(9):15622-37. PubMed ID: 25192287
[TBL] [Abstract][Full Text] [Related]
13. Tanshinone IIA inhibits endometrial carcinoma growth through the MAPK/ERK/TRIB3 pathway.
Zhang W; Liu M; Ji Y; Yu D; Ma C; Zhao J; Qu P
Arch Biochem Biophys; 2023 Jul; 743():109655. PubMed ID: 37285895
[TBL] [Abstract][Full Text] [Related]
14. [Tanshinone IIA alleviates lipopolysaccharide-induced renal tubular epithelial cell apoptosis by inhibiting RIP3/FUNDC1 signaling pathway].
Zhang S; Su B; Wang L; Tang S; Chen G
Nan Fang Yi Ke Da Xue Xue Bao; 2022 Dec; 42(12):1852-1857. PubMed ID: 36651254
[TBL] [Abstract][Full Text] [Related]
15. Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway.
Tan X; Li J; Wang X; Chen N; Cai B; Wang G; Shan H; Dong D; Liu Y; Li X; Yang F; Li X; Zhang P; Li X; Yang B; Lu Y
Int J Biol Sci; 2011 Apr; 7(3):383-9. PubMed ID: 21494433
[TBL] [Abstract][Full Text] [Related]
16. Tanshinone IIA May Inhibit Gastric Cancer via Affecting the Intestinal Microbiome.
Lu F; Zhang Y; Song P; Xu Y; Wu Z; Wang Q; Shen N
Comput Math Methods Med; 2022; 2022():6960304. PubMed ID: 36199775
[TBL] [Abstract][Full Text] [Related]
17. Tanshinone IIA: New Perspective on the Anti-Tumor Mechanism of A Traditional Natural Medicine.
Zhang W; Liu C; Li J; Lu Y; Li H; Zhuang J; Ren X; Wang M; Sun C
Am J Chin Med; 2022; 50(1):209-239. PubMed ID: 34983327
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of cytochrome P450 2J2 by tanshinone IIA induces apoptotic cell death in hepatocellular carcinoma HepG2 cells.
Jeon YJ; Kim JS; Hwang GH; Wu Z; Han HJ; Park SH; Chang W; Kim LK; Lee YM; Liu KH; Lee MY
Eur J Pharmacol; 2015 Oct; 764():480-488. PubMed ID: 26209360
[TBL] [Abstract][Full Text] [Related]
19. Effects of the combination of tanshinone IIA and puerarin on cardiac function and inflammatory response in myocardial ischemia mice.
Gao S; Li L; Li L; Ni J; Guo R; Mao J; Fan G
J Mol Cell Cardiol; 2019 Dec; 137():59-70. PubMed ID: 31629735
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway.
Wang SF; Chen MS; Chou YC; Ueng YF; Yin PH; Yeh TS; Lee HC
Oncotarget; 2016 Nov; 7(45):74132-74151. PubMed ID: 27708226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
